VTRS Viatris Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
16:15
Aug 30
Aug 30
Cheap generic drugmaker returning to growth
Druckenmiller is buying Viatris as a Teva-like generic-drug manufacturer at only about 6x earnings; the market still values it as a declining business even though it is returning to growth, and generic drug demand is defensive during crises and uncertainty.
MED
12:30
Aug 06
Aug 06
Management raised guidance for all key metrics on strong first-half performance, though tempered by supply disruptions and China policy moderation.
HIGH
18:18
Jul 26
Jul 26
Viatris cheap generic drug leader.
Viatris es un líder en fármacos genéricos que cotiza a solo 6x beneficios, en un sector defensivo y en crecimiento. El mercado sobreestima los riesgos y la compañía está extremadamente barata respecto a su media histórica, de forma similar a la oportunidad que ofreció Teva antes de doblar su valor.
HIGH
12:30
May 07
May 07
Management raised its outlook for Greater China to mid-to-high single digit growth, expects to meet or potentially exceed full-year guidance, and highlighted a 'clean' quarter with accelerating momentum.
HIGH
13:47
Mar 17
Mar 17
Viatris trades at ~5.5x forward P/E following a major restructuring, debt paydown, and a 170% jump in open job positions. The massive spike in hiring indicates growth rather than maintenance, and the upcoming October FDA date for MR-141 presents a massive TAM opportunity. A deeply undervalued turnaround play with strong institutional backing and a major pipeline catalyst. FDA rejection of MR-141 or failure to execute on the post-restructuring growth strategy.
HIGH
13:30
Feb 26
Feb 26
Management frames 2026 as a stabilization year with modest 2% top-line and EBITDA growth, supported by cost savings but offset by LOEs and supply chain disruptions. The tone is cautiously confident, emphasizing future launches and a strategic review rather than immediate acceleration.
HIGH
About VTRS Analyst Coverage
Buzzberg tracks VTRS (Viatris) across 3 sources. 3 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (50%). 6 total trade ideas tracked. Latest voices: Alejandro Estebaranz, Paul (Chief Financial Officer), Paul Campbell.